Angle PLC Announces Board Changes
ANGLE plc (OTCQX:ANPCY), a leading liquid biopsy company specializing in circulating tumour cell (CTC) solutions, announced significant leadership changes. CEO Andrew Newland and Finance Director Ian Griffiths have agreed to step down from their positions on the Board following discussions with a major shareholder.
The current Board consists of Dr. Jan Groen as Non-executive Chairman and Dr. Joseph Eid as Non-executive Director. The company plans to expand its Board membership in the future. Both departing executives have committed to supporting an orderly transition.
ANGLE plc (OTCQX:ANPCY), una destacada azienda di liquid biopsy specializzata in soluzioni basate su cellule tumorali circolanti (CTC), ha annunciato significativi cambiamenti nella leadership. Il CEO Andrew Newland e il direttore finanziario Ian Griffiths hanno accettato di lasciare i loro ruoli nel Consiglio a seguito di discussioni con un importante azionista.
Il Consiglio attuale è composto da Dr. Jan Groen come presidente non esecutivo e Dr. Joseph Eid come consigliere non esecutivo. L’azienda prevede di ampliare in futuro la composizione del Consiglio. Entrambi gli esecutivi uscenti hanno dato il loro impegno a supportare una transizione ordinata.
ANGLE plc (OTCQX:ANPCY), una importante empresa de biopsia líquida especializada en soluciones basadas en células tumorales circulantes (CTC), anunció cambios significativos en su liderazgo. El CEO Andrew Newland y el Director Financiero Ian Griffiths han acordado abandonar sus puestos en el Consejo tras conversaciones con un accionista importante.
El Consejo actual está integrado por Dr. Jan Groen como Presidente no ejecutivo y Dr. Joseph Eid como Consejero no ejecutivo. La empresa planea ampliar la membresía del Consejo en el futuro. Ambos ejecutivos salientes se han comprometido a apoyar una transición ordenada.
ANGLE plc (OTCQX:ANPCY)는 순환 종양 세포(CTC) 솔루션을 전문으로 하는 선도적인 액체 생검 기업으로, 리더십에 중대한 변화를 발표했습니다. CEO Andrew Newland와 재무 이사 Ian Griffiths은 주요 주주와의 논의 후 이사회에서 물러나기로 합의했습니다.
현재 이사회는 비상임 의장으로 Dr. Jan Groen, 비상임 이사로 Dr. Joseph Eid로 구성되어 있습니다. 회사는 향후 이사회를 확장할 계획입니다. 이직하는 두 임원 모두 원활한 이양을 지원하겠다고 약속했습니다.
ANGLE plc (OTCQX:ANPCY), une entreprise leader en biopsie liquide spécialisée dans les solutions à base de cellules tumorales circulantes (CTC), a annoncé des changements importants dans son leadership. Le PDG Andrew Newland et le directeur financier Ian Griffiths ont accepté de se retirer de leurs postes au conseil à la suite de discussions avec un actionnaire majeur.
Le conseil actuel est composé de Dr. Jan Groen en tant que président non exécutif et de Dr. Joseph Eid en tant que administrateur non exécutif. L’entreprise prévoit d’élargir les membres du conseil à l’avenir. Les deux dirigeants sortants se sont engagés à soutenir une transition ordonnée.
ANGLE plc (OTCQX:ANPCY), ein führendes Unternehmen im Bereich der Liquidbiopsie, spezialisiert auf Lösungen mit zirkulierenden Tumorzellen (CTC), gab bedeutende personelle Veränderungen bekannt. CEO Andrew Newland und Finanzvorstand Ian Griffiths haben sich nach Gesprächen mit einem bedeutenden Aktionär darauf geeinigt, ihre Positionen im Vorstand niederzulegen.
Der derzeitige Vorstand setzt sich aus Dr. Jan Groen als nicht geschäftsführender Vorsitzender und Dr. Joseph Eid als nicht geschäftsführender Direktor zusammen. Das Unternehmen plant, die Vorstandsmitglieder künftig zu erweitern. Beide scheidenden Führungskräfte haben sich verpflichtet, eine geordnete Übergabe zu unterstützen.
ANGLE plc (OTCQX:ANPCY)، شركة رائدة في فحص البلازما السائلة وتحديداً في حلول الخلايا الورمية الدائرة (CTC)، أعلنت عن تغييرات مهمة في القيادة. قرر المدير التنفيذي Andrew Newland والمدير المالي Ian Griffiths التخلي عن مناصبهما في المجلس التنفيذي بعد مناقشات مع مساهم رئيسي.
يتكون المجلس الحالي من الدكتور Jan Groen بصفته رئيساً غير تنفيذي والدكتور Joseph Eid كعضو غير تنفيذي. تخطط الشركة لتوسيع عضوية المجلس في المستقبل. كلا التنفيذيين المغادرين تعهدا بدعم انتقال منظم.
ANGLE plc (OTCQX:ANPCY)，一家在循环肿瘤细胞（CTC）解决方案领域领先的液体活检公司，宣布了重要的领导层变动。首席执行官 Andrew Newland与 财务总监 Ian Griffiths 已同意在与主要股东的讨论后辞去董事会职务。
现任董事会由 Dr. Jan Groen 担任非常任主席，Dr. Joseph Eid 担任非常任董事。公司计划在未来扩大董事会成员。两位离任高管均承诺支持一个有序的过渡。
- Board restructuring indicates responsiveness to shareholder feedback
- Commitment from departing executives to ensure smooth transition
- Plans for Board expansion suggest potential for fresh perspectives
- Loss of experienced leadership with departure of CEO and Finance Director
- Reduced Board size could temporarily impact decision-making capacity
- Uncertainty during leadership transition period
GUILDFORD, SURREY / ACCESS Newswire / September 12, 2025 / ANGLE plc (AIM:AGL)(OTCQX:ANPCY), a world-leading liquid biopsy company with innovative circulating tumour cell (CTC) solutions for use in research, drug development and clinical oncology, announces that, following feedback and discussions with a significant shareholder, Andrew Newland, Chief Executive, and Ian Griffiths, Finance Director, have agreed to step down from their positions on the Board.
They remain committed and supportive of the Company and intend to support the Company with an orderly handover.
The Board now comprises Dr. Jan Groen, Non-executive Chairman, and Dr. Joseph Eid, Non-executive Director. It is proposed that the Board be expanded in due course.
For further information:
ANGLE plc | +44 (0) 1483 343434 |
Cavendish (NOMAD and Broker) | +44 (0) 20 7220 0500 |
FTI Consulting |
|
The information contained within this announcement is deemed by the Company to constitute inside information as stipulated under the EU Market Abuse Regulation (596/2014). Upon the publication of this announcement via a regulatory information service, this information is considered to be in the public domain.
For Research Use Only. Not for use in diagnostic procedures.
For Frequently Used Terms, please see the Company's website on https://angleplc.com/investor-relations/glossary/
Notes for editors
About ANGLE plc
ANGLE is a world-leading liquid biopsy company with innovative circulating tumour cell (CTC) solutions for use in research, drug development and clinical oncology using a simple blood sample. ANGLE's FDA cleared and patent protected circulating tumour cell (CTC) harvesting technology known as the Parsortix® PC1 System enables complete downstream analysis of the sample including whole cell imaging and proteomic analysis and full genomic and transcriptomic molecular analysis.
ANGLE's commercial businesses are focusing on diagnostic products and clinical services. Diagnostic products include the Parsortix® system, associated consumables and assays. The clinical services business is offered through ANGLE's GCLP-compliant laboratories. Services include custom made assay development and clinical trial testing for pharma.
Over 115 peer-reviewed publications have demonstrated the performance of the Parsortix system. For more information, visit www.angleplc.com
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
SOURCE: ANGLE plc
View the original press release on ACCESS Newswire
FAQ
Why are ANGLE plc's CEO and Finance Director stepping down?
Who currently serves on ANGLE plc's Board after the leadership changes?
What is ANGLE plc's main business focus?
What are ANGLE plc's plans for Board composition?
How will the management transition at ANGLE plc be handled?
